drugset / Trial / NCT06159101
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects
Timeline
- Start
- 2023-11-28
- Primary completion
- 2024-05-28
- Completion
- 2024-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX13 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Comparator | Ipilimumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
Indications
No indication recorded.